Recently, Bristol Myers Squibb (BMS) announced the application of an immunomodulatory candidate drug developed by exscientia. Exscientia, an AI driven pharmaceutical technology company, has designed three drugs in phase I human clinical trials. At present, exscientia has offices in Oxford, Miami, Vienna and Osaka. On April 27, exscientia announced that it had completed the round D financing of US $225 million led by Softbank vision fund. In addition, Softbank vision fund also provided another US $300 million investment commitment, and exscientia decided whether to inject capital at its own discretion. It is understood that exscientia has two cooperation with Bristol Myers Squibb, focusing on multiple treatment fields, including oncology and immunology. In May this year, the two sides reached a cooperation agreement with a potential value of more than $1.2 billion. The licensed candidate drug targets a key immune kinase. Due to the need to combine selectivity and overall drug characteristics, it has been proved that this immune kinase is difficult to target. In order to design new drug candidates that can overcome these problems, exscientia uses its end-to-end platform to promote the discovery process, including artificial intelligence driven design, structural biology, chemistry, pharmacology and later preclinical research. Exscientia’s precision design approach focuses on simultaneously addressing parameters important to the overall therapeutic performance of the target, such as efficacy, selectivity, safety and physicochemical properties. Its AI platform is suitable for solving multi-objective design problems, so as to find new drug candidates with excellent characteristics efficiently and quickly. Andrew Hopkins, CEO of exscientia, commented: “we focus on designing accurate engineering drugs for challenging drug product characteristics with ‘patient first’ AI technology, and the efficiency of our platform is very high. This candidate drug molecule is the 150th new compound designed and tested, which was identified within 11 months after we started drug design. Through cooperation with Bristol Myers Squibb, coupled with its world-class clinical research and commercialization capabilities, we look forward to advancing the candidate drug to the next stage of development. “ Rupert Vessey, a research and development president of Bristol Myers Squibb, said: “we are pleased to obtain the license of the first candidate drug for strategic cooperation with exscientia. AI learning will continue to play an important role in drug discovery, and exscientia has provided a promising development direction in the field of immunology. We look forward to working together to further promote this candidate drug and bring more benefits to patients. “ It is understood that Bristol Myers Squibb will be responsible for the clinical and commercial development of candidate drugs. Under the terms of the agreement, exscientia will receive an option exercise fee of US $20 million, including the possibility of achieving additional development milestones and royalties for the net sales of any commercial products.
Although some health products play a great role in promoting children’s body and maintaining children’s health, this does not mean that children are suitable for all health products. If you take it blindly to children, it may have the opposite effect and have an adverse impact on the baby’s growth, development and health. Children should not abuse health care products. According to expert research, health care products containing the following ingredients are not suitable for babies:
Ginseng Ginseng is one of the common supplements, but it is not suitable for children, because it contains some substances that can accelerate children’s gonadal hormone secretion, such as ginseng, ginsenoside, etc., which are more likely to cause children to precocious puberty or disorder of the body system, which is very unfavorable to children’s physical and mental development and health.
Royal jelly The main components of royal jelly are inorganic salts, amino acids, vitamins, hormones and other substances. The composition is complex. Although taking this supplement will not cause too many negative effects for adults, it may cause precocious puberty for children.
Others Although some traditional Chinese medicines with bird’s nest, sex hormones and other substances have the effect of regulating the body, they should not be used for children, because these traditional Chinese medicines may also make children precocious puberty.
People familiar with the matter said that Softbank group has quietly established a US $5 billion stake in Roche, Switzerland, betting on the company’s strategy of using data to develop drugs and become one of Roche’s major shareholders. Softbank believes that the value of Roche’s Genentech is seriously underestimated, and the department focuses on data-based drug discovery and development. At present, Roche is developing a new pill for the new crown virus and is studying a disease treatment for Alzheimer’s disease. In June this year, the United States approved aduhelm, a drug of Biogen company for the treatment of Alzheimer’s disease, which is a positive signal for Roche.
Novartis pharmaceutical announced that the State Drug Administration approved nuoxintol on June 1 ®（ Salkubatrol (valsartan) is used to treat essential hypertension. As norcintal ®（ Following the listing of indications for heart failure in 2017, the second indication approved in China, this approval marks the breakthrough of new drugs in the field of hypertension treatment in China for more than 10 years, and is expected to lead the management mode of hypertension treatment from simple hypotension to the whole process risk control of cardiovascular events. Sacubatrovalsartan is the world’s first angiotensin receptor enkephalinase inhibitor (Arni). The results of a phase III clinical study led by Professor Huo Yong, vice chairman of China Cardiovascular Health Alliance and the first hospital of Peking University, show that after 8 weeks of treatment, the antihypertensive effect of sakubatrovalsartan is significantly better than olmesartan (control drug), which has the best antihypertensive effect among ARB drugs, and can significantly improve the compliance rate of blood pressure. A total of 1438 Asian patients with mild to moderate essential hypertension aged 18 and over (sitting systolic blood pressure ≥ 140 to < 180 mm Hg) were included in the study, of which 85% were Chinese patients. In addition, many studies have also shown that whether the blood pressure level of patients with hypertension is high or low, whether they are combined with risk factors or heart and kidney damage, sacubatrovalsartan shows universal antihypertensive effect . Hypertension is the primary risk factor for inducing cardiovascular events. As a large country of hypertension, China has 245 million adult patients with hypertension , but the standard rate of blood pressure is only 15.3% . The damage of heart, kidney, blood vessels and other organs caused by hypertension significantly increases the risk of cardiovascular death and keeps the disability and death rate related to hypertension high. Professor Huo Yong said: “the management of hypertension in China is facing multiple challenges, such as low compliance rate, high proportion of complications, aggravation of target organ damage and so on. In recent years, the treatment of hypertension began to focus on the treatment strategy based on hypotension, reducing the risk of cardiovascular events and improving the prognosis of patients. In terms of blood pressure reduction, sakubatrovalsartan shows the characteristics of large reduction, rapid onset and 24-hour pressure control. At the same time, it also shows superior protective effects on organs such as heart, kidney and blood vessels. It can block the chain of cardiovascular events in multiple ways and reduce the risk of cardiovascular events. The application of salkubatrol and Valsartan in the field of hypertension will further optimize the existing treatment scheme, which is of milestone significance to the management of hypertension. “